Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists

Journal of Pharmacological and Toxicological Methods

Volumn 56, Issue 3, 2007, Pages 308-316

  Carballo Jane, Ester ^a   Gerckens, Lynn S ^a   Luell, Silvi ^a   Parlapiano, Allison S ^a   Wolff, Michael ^a   Colletti, Steven L ^a   Tata, James R ^a   Taggart, Andrew K P ^a   Waters, M Gerard ^a   Richman, Jeremy G ^b   McCann, Margaret E ^a   Forrest, Michael J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ARENA PHARMACEUTICALS   (United States)

Author keywords

Acipimox; Dog; GPR109A; Lipolysis; Methods; Nicotinic acid; Rat; Therapeutic index; Vasodilatation

Indexed keywords

ACIPIMOX; ASCRIPTIN; FATTY ACID; INDOMETACIN; NICOTINIC ACID; PROSTAGLANDIN D2;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; EAR; FATTY ACID BLOOD LEVEL; LASER DOPPLER FLOWMETRY; LIPOLYSIS; MALE; NONHUMAN; PROSTAGLANDIN RELEASE; RAT; SPECIES COMPARISON; SPECTROMETER; TISSUE PERFUSION; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; FATTY ACIDS, NONESTERIFIED; INDOMETHACIN; INHIBITORY CONCENTRATION 50; INJECTIONS, SUBCUTANEOUS; LIPOLYSIS; MALE; MODELS, ANIMAL; NIACIN; NICOTINIC AGONISTS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; VASODILATION;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 35148856217     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.05.007     Document Type: Article

References (31)

1. Andersson R.G., Aberg G., Brattsand R., Ericsson E., and Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacologica et Toxicologica (Copenhagen) 41 1 (1977) 1-10
2. Benyo Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. Journal of Clinical Investigation 115 12 (2005) 3634-3640
3. Carballo-Jane E., Ciecko T., Luell S., Woods J.W., Zycband E.I., Waters M.G., et al. Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse. Inflammation Research 56 6 (2007) 254-261
4. Carlson L.A. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 258 2 (2005) 94-114
5. Carlson L.A. Nicotinic acid and other therapies for raising high-density lipoprotein. Current Opinion in Cardiology 21 4 (2006) 336-344
6. Cheng K., Wu T.J., Wu K.K., Sturino C., Metters K., Gottesdiener K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of the United States of America 103 17 (2006) 6682-6687
7. Edlund A., Musatti L., and Wennmalm A. Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism. European Journal of Clinical Pharmacology 39 1 (1990) 37-41
8. Eklund B., Kaijser L., Nowak J., and Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17 6 (1979) 821-830
9. Fuccella L.M., Goldaniga G., Lovisolo P., Maggi E., Musatti L., Mandelli V., et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clinical Pharmacology and Therapeutics 28 6 (1980) 790-795
10. Hom G.J., Forrest M.J., Bach T.J., Brady E., Candelore M.R., Cascieri M.A., et al. Beta(3)-adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 297 1 (2001) 299-307
11. Kaijser L., Eklund B., Olsson A.G., and Carlson L.A. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Medical Biology 57 2 (1979) 114-117
12. Kaniaris P., Lekakis D., Kykoniatis M., and Kastanas E. Serum free fatty acid and blood sugar levels in children under halothane, thiopentone and ketamine anaesthesia (comparative study). Canadian Anaesthetists Society Journal 22 4 (1975) 509-518
13. Lipson M.J., Naimi S., and Proger S. Effect of a combination of propranolol and nicotinic acid on the inhibition of norepinephrine-induced elevations of serum triglyceride, serum glycerol, and plasma free fatty acids in the dog. Metabolism 20 6 (1971) 580-589
14. Lipson M.J., Naimi S., and Proger S. Synergistic effect of propranolol and nicotinic acid on the inhibition of plasma free fatty acid release in the dog. Circulation Research 28 2 (1971) 270-276
15. Lorenzen A., Stannek C., Burmeister A., Kalvinsh I., and Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochemical Pharmacology 64 4 (2002) 645-648
16. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., and Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Molecular Pharmacology 59 2 (2001) 349-357
17. Lovisolo P.P., Briatico-Vangosa G., Orsini G., Ronchi R., and Angelucci R. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity. Pharmacological Research Communications 13 2 (1981) 163-174
18. Lovisolo P.P., Briatico-Vangosa G., Orsini G., Ronchi R., Angelucci R., and Valzelli G. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action. Pharmacological Research Communications 13 2 (1981) 151-161
19. Morrow J.D., Parsons III W.G., and Roberts II L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 2 (1989) 263-274
20. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends in Pharmacological Sciences 27 7 (2006) 384-390
21. Pereira J.N. The plasma free fatty acid rebound induced by nicotinic acid. Journal of Lipid Research 8 (1967) 239-244
22. Pereira J.N., and Holland G.F. The development of resistance to a potent lipolysis inhibitor, 3-methylisoxazole-5-carboxylic acid. Journal of Pharmacology and Experimental Therapeutics 157 2 (1967) 381-387
23. Pontiroli A.E., Fattor B., Pozza G., Pianezzola E., Strolin Benedetti M., and Musatti L. Acipimox-induced facial skin flush: Frequency, thermographic evaluation and relationship to plasma acipimox level. European Journal of Clinical Pharmacology 43 2 (1992) 145-148
24. Renauld A., and Sverdlik R.C. Pentobarbital anaesthesia. Effects on blood sugar, serum immunoreactive insulin and free fatty acid responses to glucose. Experientia 31 4 (1975) 474-475
25. Seed M., O'Connor B., Perombelon N., O'Donnell M., Reaveley D., and Knight B.L. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 101 1 (1993) 61-68
26. Soga T., Kamohara M., Takasaki J., Matsumoto S., Saito T., Ohishi T., et al. Molecular identification of nicotinic acid receptor. Biochemical and Biophysical Research Communications 303 1 (2003) 364-369
27. Toso C.F., Rodriguez R.R., Renauld A., Sverdlik R.C., and Linares L.M. Blood sugar, serum insulin and serum non-esterified fatty acid levels during thiopentone anaesthesia in dogs. Canadian Journal of Anaesthesia 40 1 (1993) 38-45
28. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Medicine 9 3 (2003) 352-355
29. Tunaru S., Lattig J., Kero J., Krause G., and Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Molecular Pharmacology 68 5 (2005) 1271-1280
30. Turenne S.D., Seeman M., and Ross B.M. An animal model of nicotinic-acid-induced vasodilation: Effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophrenia Research 50 3 (2001) 191-197
31. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., et al. Molecular identification of high and low affinity receptors for nicotinic acid. Journal of Biological Chemistry 278 11 (2003) 9869-9874